DNA hypermethylation of CADM1, PAX5, WT1, RARβ, and PAX6 genes in oropharyngeal cancer associated with human papillomavirus

Epigenetics ◽  
2022 ◽  
pp. 1-10
Author(s):  
Natália Birknerová ◽  
Helena Kovaříková ◽  
Ivana Baranová ◽  
Albína Přikrylová ◽  
Jan Laco ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Dna Hypermethylation

Redefining risk of contralateral cervical nodal disease in early stage oropharyngeal cancer in the human papillomavirus era

Head & Neck ◽  
2021 ◽  
Author(s):  
Andrew W. Smith ◽  
Matthew Gallitto ◽  
Eric J. Lehrer ◽  
Isaac Wasserman ◽  
Vishal Gupta ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Early Stage ◽  
Nodal Disease

scholarly journals Value and Unmet Needs in Non-Invasive Human Papillomavirus (HPV) Testing for Oropharyngeal Cancer

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 562
Author(s):  
Alec J. Kacew ◽  
Glenn J. Hanna
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Unmet Needs ◽  
Hpv Testing ◽  
Testing Methods ◽  
Blood Samples ◽  
Non Invasive

The burden of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has risen, now representing the most common HPV-related malignancy. For years, researchers have explored the utility of measuring HPV-related markers from mouth, throat, and blood samples, often with the aim of gathering more information about an existing HPV-related tumor in a given patient. We review the widely varying methods for collecting and testing saliva and blood samples and offer guidance for standardizing these practices. We then review an array of clinical contexts in which non-invasive testing holds the most promise for potentially addressing unmet needs. In particular, such testing could help clinicians and researchers monitor the effects of vaccination and treatment. Meanwhile, due to the currently incomplete understanding of how carrying HPV relates to infection and subsequent oncogenesis, non-invasive testing methods may not be suitable for the screening setting at this time.

scholarly journals Pathogenic Role of Immune Evasion and Integration of Human Papillomavirus in Oropharyngeal Cancer

2021 ◽  
Vol 9 (5) ◽  
pp. 891
Author(s):  
Takashi Hatano ◽  
Daisuke Sano ◽  
Hideaki Takahashi ◽  
Nobuhiko Oridate
Keyword(s):  
Human Papillomavirus ◽  
Immune Evasion ◽  
Oropharyngeal Cancer ◽  
Current Knowledge ◽  
Immune Evasion Mechanism ◽  
Cell Cycle Activation ◽  
Genome Integration ◽  
Integration Mechanisms ◽  
E6 And E7

The incidence of oropharyngeal cancer (OPC) is increasing remarkably among all head and neck cancers, mainly due to its association with the human papillomavirus (HPV). Most HPVs are eliminated by the host’s immune system; however, because HPV has developed an effective immune evasion mechanism to complete its replication cycle, a small number of HPVs are not eliminated, leading to persistent infection. Moreover, during the oncogenic process, the extrachromosomal HPV genome often becomes integrated into the host genome. Integration involves the induction and high expression of E6 and E7, leading to cell cycle activation and increased genomic instability in the host. Therefore, integration is an important event in oncogenesis, although the associated mechanism remains unclear, especially in HPV-OPC. In this review, we summarize the current knowledge on HPV-mediated carcinogenesis, with special emphasis on immune evasion and integration mechanisms, which are crucial for oncogenesis.

Proteomic Alterations in Salivary Exosomes Derived from Human Papillomavirus-Driven Oropharyngeal Cancer

2021 ◽  
Author(s):  
Kai Dun Tang ◽  
Yunxia Wan ◽  
Xi Zhang ◽  
Natalie Bozyk ◽  
Sarju Vasani ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer

scholarly journals An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chengxue Zhong ◽  
Li Xu ◽  
Ho-Lan Peng ◽  
Samantha Tam ◽  
Li Xu ◽  
...  
Keyword(s):  
Public Health ◽  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Hpv Vaccine ◽  
Health Benefits ◽  
Incidence Rates ◽  
Vaccine Uptake ◽  
Males And Females ◽  
Quality Adjusted Life ◽  
The U.S

AbstractIn 2017, 46,157 and 3,127 new oropharyngeal cancer (OPC) cases were reported in the U.S. and Texas, respectively. About 70% of OPC were attributed to human papillomavirus (HPV). However, only 51% of U.S. and 43.5% of Texas adolescents have completed the HPV vaccine series. Therefore, modeling the demographic dynamics and transmission of HPV and OPC progression is needed for accurate estimation of the economic and epidemiological impacts of HPV vaccine in a geographic area. An age-structured population dynamic model was developed for the U.S. state of Texas. With Texas-specific model parameters calibrated, this model described the dynamics of HPV-associated OPC in Texas. Parameters for the Year 2010 were used as the initial values, and the prediction for Year 2012 was compared with the real age-specific incidence rates in 23 age groups for model validation. The validated model was applied to predict 100-year age-adjusted incidence rates. The public health benefits of HPV vaccine uptake were evaluated by computer simulation. Compared with current vaccination program, increasing vaccine uptake rates by 50% would decrease the cumulative cases by 4403, within 100 years. The incremental cost-effectiveness ratio of this strategy was $94,518 per quality-adjusted life year (QALY) gained. Increasing the vaccine uptake rate by 50% can: (i) reduce the incidence rates of OPC among both males and females; (ii) improve the quality-adjusted life years for both males and females; (iii) be cost-effective and has the potential to provide tremendous public health benefits in Texas.

Sign in / Sign up

Export Citation Format

Share Document